Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | JUN | P05412 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 6/20 | 0.42 |
| ▸ | RAB9A | P51151 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2311117 | 0.88 | ALDH1A1 (0.54) | MAPTJUNNFKB1ALDH1A1CYP19A1 | |
| SCHEMBL11055537 | 0.84 | NPC1 (0.48) | MAPTALDH1A1CYP19A1CYP11B2NPC1 | |
| SCHEMBL3750399 | 0.84 | CYP19A1 (0.48) | MAPTLMNACYP19A1CYP11B2NPC1 | |
| SCHEMBL138489 | 0.79 | MAPT (0.61) | MAPTLMNAJUNNFKB1ALDH1A1 | |
| SCHEMBL107198 | 0.79 | MAPT (0.61) | MAPTLMNAJUNNFKB1ALDH1A1 | |
| SCHEMBL5887491 | 0.78 | MAPT (0.77) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL11090821 | 0.78 | CYP1A2 (0.77) | MAPTLMNAALDH1A1NPC1RAB9A | |
| SCHEMBL9966009 | 0.76 | MAPT (0.65) | MAPTLMNAJUNNFKB1ALDH1A1 | |
| SCHEMBL31175769 | 0.76 | MAPT (0.58) | MAPTLMNAJUNNFKB1ALDH1A1 | |
| SCHEMBL135604 | 0.76 | MAPT (0.65) | MAPTLMNAJUNNFKB1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3933800-A | O-SUBSTITUTED OXIMES, MICROBIOCIDES | GRUPPO LEPETIT S.P.A. (IT) | 1976-01-20 | — | — | US | claimed |
| EP-2994469-B1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES INC (US) | 2018-12-19 | — | — | EP | disclosed |
| US-20180311247-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | GILEAD SCIENCES, INC. | 2018-11-01 | — | — | US | disclosed |
| US-20180282316-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GILEAD SCIENCES, INC. | 2018-10-04 | — | — | US | disclosed |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | GILEAD SCIENCES, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| WO-2018106444-A1 | TREATMENT OF BREAST CANCER BY CONCOMITANT ADMINISTRATION OF A BROMODOMAIN INHIBITOR AND A SECOND AGENT | GILEAD SCIENCES, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| WO-2018106433-A1 | TREATMENT OF PROSTATE CANCER BY CONCOMITANT ADMINISTRATION OF A BROMODOMAIN INHIBITOR AND A SECOND AGENT | GILEAD SCIENCES, INC. (US) | 2018-06-14 | — | — | WO | disclosed |
| US-20180153867-A1 | TREATMENT OF PROSTATE CANCER BY CONCOMITANT ADMINISTRATION OF A BROMODOMAIN INHIBITOR AND A SECOND AGENT | GILEAD SCIENCES, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180153868-A1 | TREATMENT OF BREAST CANCER BY CONCOMITANT ADMINISTRATION OF A BROMODOMAIN INHIBITOR AND A SECOND AGENT | GILEAD SCIENCES, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | GILEAD SCIENCES, INC. | 2018-05-17 | — | — | US | disclosed |
| US-20120053346-A1 | Pyrimidine Carboxamide Derivatives | MAEHR HUBERT (US) | 2012-03-01 | — | — | US | disclosed |
| CN-101107000-A | 3,6-bicyclolides | ENANTA PHARM INC (US) | 2008-01-16 | — | — | CN | disclosed |
| US-5622953-A | DRUG RESISTANT TO ANTICANCER CHEMOTHERAPEUTIC DRUG | BASF AKTIENGESELLSCHAFT (DE) | 1997-04-22 | — | — | US | disclosed |
| EP-0691962-A1 | 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE | BASF AKTIENGESELLSCHAFT (DE) | 1996-01-17 | — | — | EP | disclosed |
| US-5405843-A | Anticancer drug potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1995-04-11 | — | — | US | disclosed |
| EP-0363212-B1 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS (JP) | 1995-01-04 | — | — | EP | disclosed |
| WO-1994022842-A1 | 1-AMINO-3-PHENOXY PROPANE DERIVATIVES AS MODULATORS OF MULTI-DRUG RESISTANCE | BASF AKTIENGESELLSCHAFT (DE) | 1994-10-13 | — | — | WO | disclosed |
| US-5204348-A | Quinoline derivatives | MITSUI TOATSU CHEMICALS INC. (JP) | 1993-04-20 | — | — | US | disclosed |
| US-5112817-A | Anticancer Drug Potentiators | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1992-05-12 | — | — | US | disclosed |
| EP-0363212-A2 | Novel heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133212-A1 | COMBINATION OF A BCL-2 INHIBITOR AND A BROMODOMAIN INHIBITOR FOR TREATING CANCER | BCL2, BAK1, BRD4 | MAPT 2995/4885LMNA 2117/4885JUN 255/4885 |
| US-20180282316-A1 | BENZIMIDAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | MAPT 1649/4885LMNA 1185/4885JUN 787/4885 |
| US-20120053346-A1 | Pyrimidine Carboxamide Derivatives | NOD1, IL1B, IRAK1 | MAPT 4026/4885LMNA 3633/4885JUN 564/4885 |
| US-20180153867-A1 | TREATMENT OF PROSTATE CANCER BY CONCOMITANT ADMINISTRATION OF A BROMODOMAIN INHIBITOR AND A SECOND AGENT | BRDT, BRD4, BRD2 | MAPT 2479/4885LMNA 3557/4885JUN 2966/4885 |
| US-20180311247-A1 | COMBINATION THERAPIES FOR TREATING CANCERS | BRD4, JAK2, JAK1 | MAPT 2830/4885LMNA 4226/4885JUN 318/4885 |
| US-10017501-B2 | Benzimidazole derivatives as bromodomain inhibitors | BRD4, BRD3, BRD1 | MAPT 1649/4885LMNA 1185/4885JUN 787/4885 |
| US-20180153868-A1 | TREATMENT OF BREAST CANCER BY CONCOMITANT ADMINISTRATION OF A BROMODOMAIN INHIBITOR AND A SECOND AGENT | BRDT, BRD4, BRD2 | MAPT 3600/4885LMNA 4215/4885JUN 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.